Bibliografía del artículo
1. Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bulletin of the World Health Organization 81:61-70, 2003.
2. Abzug M. Vaccination in the immunocompromised child. Pediatr Infect Dis J 28:233-36, 2009.
3. Eley BS. Immunization in patients with HIV infection. Drugs 68:1473-81, 2008.
4. Obaro SK, Pugatch D, Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1 infected children. Lancet Infect Dis 4:510-18, 2004.
5. Madhi SA, Kuwanda L, Cutland C, Holm A, Käyhty H, Klugman KP. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 24:410-16, 2005.
6. Pensieroso S, Cagigi A, Palma P et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically infected children. PNAS 106:7939-44, 2009.
7. Siriaksorn S, Puthanakit T, Sirisanthana T, Sirisanthana, V. Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine 24:3095-99, 2006.
8. Lao-Araya M, Puthanakit T, Aurpibul L, Sirisanthana T, Sirisanthana V. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Vaccine 25:5324-29, 2007.
9. Abzug M, Warshaw M, Rosenblatt HM, et al. Immunogenicity and immunologic memory after Hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis 200:935-46, 2009.
10. Pessoa SD, Miyamoto M, Ono E, et al. Persistence of vaccine immunity against hepatitis B virus and response to revaccination in vertically HIV-infected adolescents on HAART. Vaccine 28:1606-12, 2010.
11. Pippi F, Bracciale L, Stolzuoli L, et al. Serological response to hepatitis B vaccine in HIV-infected children in Tanzania. HIV Medicine 9:519-25, 2008.
12. Ching N, Deville JG, Nielsen KA, Ank B et al. Cellular and humoral immune response to a tetanus toxoid booster in perinatally HIV-infected children and adolescents receiving highly active antiretroviral therapy. Eur J Pediatr 166:51-56, 2007.
13. Farquhar C, Wamalwa D, Selig S, et al. Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and re-vaccination. Pediatr Infect Dis J 28:295-99, 2009.
14. Rosenblatt HM, Song LY, Nachman SA, et al. Tetanus immunity after diphtheria, tetanus toxoids and acellular pertussis vaccination in children with clinically stable HIV infection. J Allergy Clin Immunol 116:698-703, 2005.
15. Abzug MJ, Song LY, Fenton T, et al. Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Pediatrics 120:e1190-1202, 2007.
16. Choudhury SA, Mishreki NK. Subnormal immunity to Hemophilus influenzae type b (Hib) in previously vaccinated human immunodeficiency virus-infected children 59 months of age or older and response to booster doses of the conjugate vaccine. Clin Pediatr 43:831-35, 2004.
17. Chokephaibulkit K, Phongsamart W, Vanprapar N, Chotpitayasunondh T, Chearskul S. Catch-up vaccination against Haemophilus influenzae type b in human immunodeficiency virus-infected Thai children older than 2 years old. Vaccine 22:2018-22, 2004.
18. Spoulou VI, Tsoumas DL, Papaevangelou VG, Mostrou GI, Theodoridou MC. Haemophilus influenzae type b conjugate vaccine-induced immunological memory in symptomatic HIV-1 infected children. AIDS 17:1396-98, 2003.
19. Madhi SA, Petersen K, Madhi A, Wasas A, Klugman KP. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J 19:1141-47, 2000.
20. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. NEJM 349:1341-48, 2003.
21. Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 25:2451-57, 2007.
22. Madhi SA, Adrian P, Cotton MF, et al. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis 202:355-61, 2010.
23. Costa Ide C, Guilardi F, Kmiliauskis MA, Arslanian C, Baldacci ER. Evaluation of humoral response to heptavalent pneumococcal conjugate vaccine in HIV-infected children. Rev Saude Publica 42:844-50, 2008.
24. Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 25:920-25, 2006.
25) Influenza vaccine: WHO position paper. Weekly epidemiological record. 2005: Accessed 10/8/2010. www.who.int/immunization/wer8033influenza_August2005_position_paper.pdf.
26. Zuccotti GV, Zenga A, Durando P, et al. Immunogenicity and tolerability of a trivalent virosomal influenza vaccine in a cohort of HIV-infected children. J Int Med Res 32:492-99, 2004.
27. Montoya CJ, Toro MF, Aguirre C, et al. Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy. Mem Inst Oswaldo Cruz 102:501-8, 2007.
28. Viganò A, Zuccotti GV, Pacei M, et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 48:289-96, 2008.
29. Amendola A, Pariani E, Viganò A, et al. Influenza surveillance in a cohort of HIV-infected children and adolescents immunized against seasonal influenza. Vaccine 28:2700-4, 2010.
30. Violari A, Dittmer S, Cassim H, et al. Efficacy and immunogenicity if trivalent inactivated influenza vaccine (TIV) in HIV-infected children: a randomized, double blind, placebo-controlled trial. The XVIII International AIDS conference: Abstract no. MOPE0207.
31. Levin MJ, Moscicki AB, Song LY, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (Types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010 [Epub ahead of print].
32. Weinberg A, Gona P, Nachman SA, et al. Antibody response to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis 193:302-11. 2006.
33. Siberry GK, Coller RJ, Henkle E. Antibody response to hepatitis A immunization among human immunodeficiency virus-infected children and adolescents. Ped Infect Dis J 27:465-7, 2008.
34. Siberry GK, Williams PL, Lujan-Zilbermann J, et al. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (Groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Ped Infect Dis J 29:391-6, 2010.
35. Puthanakit T, Aurpibul L, Yoksan S, Sirisanthana T, Sirisanthana V. Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine 25:8257-61, 2007·
36. Chokephaibulkit K, Plipat N, Yoksan S, et al. A comparative study of the serological response to Japanese encephalitis vaccine in HIV-infected and uninfected Thai children. Vaccine 28:3563-6, 2010.
37. Moss, WJ, Scott S, Mugala N, et al. Immunogenicity of standard-titer measles vaccine in HIV-1 -infected and uninfected Zambian children: An observational study. J Infect Dis 196:347-55, 2007.
38. Aurpibul L, Puthanakit T, Siriaksorn S, Sirisanthana T, Sirisanthana V. Prevalence of protective antibody against measles in HIV-infected children with immune recovery after highly active antiretroviral therapy. HIV Medicine 7:467-70, 2006.
39. Melvin AJ, Mohan KM. Response to immunization with measles, tetanus and haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics 111:e641-44, 2003.
40. Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaaijer H, Kuijpers TW. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: Loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatr 118:e315-322, 2006.
41. Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clinical Infectious Diseases 32:1090-4, 2001.
42. Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Response to measles, mumps, and rubella Revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clinical Infectious Diseases 45:637-42, 2007.
43 Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Persistence of measles, mumps and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy. Clinical Infectious Diseases 50:1415-18, 2010.
44. Pracanica A, Russo P, Zaccarelli-Filho R, et al. Response to primary immunization to tetanus, diphtheria, H. influenzae type b and measles in HIV-infected children on HAART. Oral abstract: 9th Conference on Retroviruses and Opportunistic Infections 2002.
45. Lima M, De Menzes Succi RC, Nunes Dos Santos AM, Weckx LY, De Moraes-Pinto MI. Rubella immunization in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 23:604-7, 2004.
46. Tejiokem MC, Gouandjika I, Béniguel L, et al. HIV-infected children living in Central Africa have low persistence of antibodies to vaccines used in the expanded program on immunization. PLoS ONE 2:e1260, 2007.
47. Chitsike I, Van Furth R. Paralytic poliomyelitis associated with live oral poliomyelitis vaccine in child with HIV infection in Zimbabwe: case report. BMJ 318:841-3, 1999.
48. Ion-Nedelcu N, Dobrescu A, Strebel PM, Sutter RW. Vaccine-associated paralytic poliomyelitis and HIV infection. Lancet 343:51-2, 1994.
49. Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr 139:305-10, 2001.
50. Levin MJ, Gershon AA, Weinberg A, et al. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4+ T cells. J Infect Dis 194:247-55, 2006.
51. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56(RR-4):1-40, 2007.
52. Bekker V, Westerlaken GHA, Scherpbier H, et al. Varicella vaccination in HIV-1-infected children after immune reconstitution. AIDS 20:2321-29, 2006.
53. Armenian SH, Han JY, Dunaway TM, Church JA. Safety and immunogenicity of live varicella vaccine in children with Human Immunodeficiency virus type 1. Pediatr Infect Dis 25:368-370, 2006.
54. Wise RP, Salive ME, Miles Braun, M, et al. Post-licensure safety surveillance for varicella vaccine. JAMA 284:1271-79, 2000.
55. Son MS, Shapiro ED, LaRussa P, et al. Effectiveness of varicella vaccine in children infected with HIV. J Infect Dis 201:1806-10, 2010.
56. Rotavirus vaccines: an update - Position Paper. Weekly Epidemiological Record. 2009; Accessed 20/08/2010. www.who.int/wer/2009/wer8451_52.pdf.
57. Steele AD, Cunliffe N, Tumbo J, Madhi SA, De Vos B, Bouckenooghe A. A review of rotavirus infection in and vaccination of human immunodeficiency virus-infected children. J Infect Dis 200(Suppl.1):S57-62, 2009.
58. Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 48:659-66, 2009.
59. Revised BCG vaccination guidelines for infants at risk for HIV infection - WHO position paper. Weekly Epidemiological Record. 2007; Accessed 21/7/2010. www.who.int/immunization/wer8221bcg_May07_position_paper.pdf.
60. Hesseling AC, Cotton MF, Fordham von Reyn C, Graham SM, Gie RP, Hussey GD. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis 12:1376-9, 2008.
61. Hessling AC, Marais BJ, Gie RP et al. The risk of disseminated bacillus Calmette-Guérin (BCG) disease in HIV-infected children. Vaccine 25:14-18, 2007.
62. Fallo A, Torrado L, Sanches A, Cerqueiro C, Schargrodsky L, Lopez EL. Delayed complications of bacillus Calmette-Guérin (BCG) vaccination in HIV-infected children. International AIDS society conference, Rio de Janeiro, Brazil, 24-27 July 2005.
63. Nuttall JJ, Davies MA, Hussey GD, Eley BS. Bacillus Calmette-Guérin vaccine-induced complications in children treated with highly active antiretroviral therapy. Int J Infect Dis 12:e99-105, 2008.
64. Rabie H, Violari A, Madhi S, et al. Complications of BCG vaccination in HIV-infected and -uninfected children: (Children with HIV Early Antiretroviral Therapy) CHER Study. 15th Conference on Retroviruses and Opportunistic Infections, Boston, 3-6 February 2008. Abstract #600.